Compared to the control groups, there were no statistically significant differences in the risk of new-onset diabetes among various PCSK9 inhibitors (high certainty) (Figure 5A), ranked by SUCRA values as follows (Figure 5B): alirocumab (0.70), oral lipid-lowering drugs (0.62), evolocumab (0.4), and inclisiran (0.28). The gene discussed is PCSK9; the disease is diabetes mellitus.